Discontinuation of Treatment Using Anticholinergic Medications in Patients With Urinary Incontinence

@article{Kalder2014DiscontinuationOT,
  title={Discontinuation of Treatment Using Anticholinergic Medications in Patients With Urinary Incontinence},
  author={Matthias Kalder and Konstantinos D. Pantazis and Konstantinos D. Dinas and U-s. Albert and Christina Heilmaier and Karel Kostev},
  journal={Obstetrics \& Gynecology},
  year={2014},
  volume={124},
  pages={794–800}
}
OBJECTIVE: To evaluate the discontinuation rates of anticholinergics prescribed in patients with urinary incontinence (UI). METHODS: Data from a Disease Analyzer database including 988 general, 95 urologist, and 203 gynecologic practices were examined. Twenty six thousand eight hundred thirty-four patients were identified as having received a first-time anticholinergic prescription for UI, namely darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine, or trospium, between… 
View on Wolters Kluwer
journals.lww.com
21 Citations
Background Citations
6
Results Citations
3

21 Citations

Citation Type

Citation Type

Comparative Effectiveness of Anticholinergic Agents for Lower Urinary Tract Symptoms.
TLDR
Evidence is found for superior effectiveness of solifenacin and fesoterodine relative to other anti-cholinergics and for long- acting formulations over short-acting formulations for lower urinary tract symptoms.
Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence.
TLDR
Patients taking newer anticholinergics are at at least as likely to change therapy as those taking oxybutynin, and patients taking newer anti-cholinergic medications are at least more likely than those taking current therapy to change their prescription.
Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?
TLDR
Persistence on OAB pharmacotherapy was higher among FPMRS patients than among GU and IM patients in this community setting, and results suggest that persistence is higher under subspecialist supervision.
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
TLDR
Patients with OAB in Spain who received mirabegron experienced longer persistence on-treatment than those who received antimuscarinics and the proportion of patients persistent on- treatment at 12 months with mirabEGron was two-times higher versus antimus carinics.
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
TLDR
Most patients with OAB discontinued oral OAB pharmacotherapy and were non-adherent 1 year after treatment initiation, and in general, mirabegron was associated with greater persistence and adherence compared with antimuscarinics.
Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany
TLDR
A comparison of propiverine ER (once-daily administration) and trospium chloride IR (in a multiple dose administration) in patients with OAB syndrome demonstrates that there are substantial differences in the odds of a follow-up prescription.
Fecal and urinary incontinence are major problems associated with rectal cancer
TLDR
It appears that the awareness of this fact needs to be improved among general practitioners since the data show lower percentages of fecal and urinary incontinence diagnoses compared with the percentages for specialized centers reported in the literature.
Comparison of solifenacin and fesoterodine in treatment of overactive bladder
TLDR
No significant difference was found between the OABSS of these 2 drugs, however, discontinuation of drugs due to side effects was more frequent in fesoterodine.
Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study
TLDR
This study suggests medium-term efficacy and safety but a high re-operation rate of SNM in patients with refractory OAB.
Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse
TLDR
Sacral neuromodulation improves bladder symptoms in women with prior SUI/POP surgery, but response may be slightly less in those with prior surgery due to underlying bladder or pelvic floor issues.
...
1
2
3
...

References

SHOWING 1-10 OF 23 REFERENCES
Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms
TLDR
Discontinuation rates for anticholinergic medications are high regardless of the class of medication used, according to a large administrative database used for this study.
Persistence with overactive bladder pharmacotherapy in a Medicaid population.
TLDR
Persistence rates are better for patients taking drugs with once-daily dosing, but there is a need for a better understanding of non-persistent patients.
Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.
TLDR
Both persistence and adherence with medication treatment were suboptimal for chronic OAB/UI patients identified in this study, and it is suggested that persistence and treatment discontinuation remains problematic for the Oab/UI population.
Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation
TLDR
Tolterodine was safe and generally well tolerated and the incidence of dry mouth, as the most commonly reported adverse event, was only 9% and of mild to moderate intensity.
Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.
TLDR
Tolterodine was safe and generally well tolerated and the incidence of dry mouth, as the most commonly reported adverse event, was only 9% and of mild to moderate intensity.
Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database.
TLDR
Treatment using the intravenous route and PTH showed the highest persistence and compliance rates and daily oral bisphosphonates the lowest and more effort to improve treatment compliance and persistence is needed to assure clinical efficacy.
A review of adherence to drug therapy in patients with overactive bladder
TLDR
Methods of measuring, and factors affecting, adherence to pharmacotherapy in patients with OAB are outlined, and psychological and social variables that might alter patients’ perception of the benefits of taking medication are outlined.
Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome
TLDR
Urgency should be the primary or co-primary endpoint for future studies of OAB and detrusor overactivity and greater clarity is needed in the development of instruments for measuring urgency so that they do not confuse urgency with normal bladder sensations.
Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder
TLDR
Tolterodine has equivalent efficacy to oxybutynin, but with less severe adverse effects, which will allow patients to receive more effective treatment for their condition, with better compliance.
...
1
2
3
...